E-Therapeutics depression drug trials miss targets
15th Feb 2016 09:45
(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower. Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic ant
Read moreDaily Mail General Trust's Chairman sells £15.91m-worth of shares
4th Jul 2014 16:30
Viscount Rothermere, the Chairman of Daily Mail and General Trust, has traded in £15.91m-worth of shares in the multi-media and information company. Selling the stock at 860p a piece, Rothermere benefited from the rise seen in the group's share price this week, which has seen it climbed 5.56%, or
Read moreWife of DS Smith CEO sells 5.6m-pound stake
24th Jul 2013 15:53
The wife of DS Smith frontman Miles Roberts sold a substantial sum of shares in the packaging and office supplies firm on the same day it was revealed the Chief Executive Officer (CEO) received a big pay increase last year. The move came on Tuesday, the same day DS Smith released its annual report
Read moree-Therapeutics pleases with pipeline progress
14th May 2013 09:46
News from biotech company e-Therapeutics about the progress of two clinical trials for its cancer drug pleased the markets on Tuesday. The AIM-listed company provided first findings for the company's ETS2101 drug candidate in Phase I trials in the US for patients with brain cancer and in the UK fo
Read moreTuesday broker round-up UPDATE
14th May 2013 08:04
Babcock International: Jefferies increases target price from 1080p to 1250p and maintains a buy recommendation. Barratt Developments: Bank of America takes target price from 265p to 325p, while downgrading to neutral. Belgravium Technologies: WH Ireland places both its target price and its neutral
Read moreFriday broker round-up UPDATE
10th May 2013 07:14
Afren: Westhouse Securities initiates with a target price of 160p and a buy recommendation. Ashmore Group: Credit Suisse raises target price from 375p to 440p upgrading from underperform to neutral. Barratt Developments: Citigroup increases target price from 245p to 315p leaving its neutral rating
Read moreDebenhams Executive Director adds to stake
19th Feb 2013 16:21
Michael Sharp, the Executive Director of retail chain Debenhams, has topped up his stake in the group with the purchase of 50,000 shares. Sharp, who has been in his current role since September 2011, bought the shares at 97.20p for a total of £48,598. He now holds 6.2m shares in the company. Debe
Read moree-Therapeutics shares jump following 40m equity issue
11th Feb 2013 09:15
Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday. Following the proposed issu
Read moreTuesday broker round-up
23rd Oct 2012 09:23
Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept. ARM Holdings: Investec keeps buy rating and 800p target. Avacta: Panmure Gordon keeps buy rating and 1.75p target. AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept. Babcock: JPMorgan Cazenove ups targe
Read moreMonday broker round-up - UPDATE
22nd Oct 2012 08:19
888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl
Read moree-therapeutics produces mixed interims
22nd Oct 2012 07:53
e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug. As expected, first half losses increased to £1.8m (2011: loss of £1.5m), reflecting increased investment in the business. The company ha
Read moreBramson vehicle buys more shares in F&C
15th Mar 2011 17:05
F&C Asset Management chairman Edward Bramson's investment vehicle SIGA LP has acquired more shares in the asset management company. Bramson was appointed chairman of F&C last month after a shareholder coup removed the previous incumbent, along with another non-executive, and appointed three new di
Read moreWife of outgoing FD sells British Land shares
14th Mar 2011 17:19
Diane Roberts, the wife of British Land finance director Graham Roberts, has raised more than £1m by selling more than three-quarters of the couple's stake in the property investor. She sold 191,780 shares at 562.8p each, which raised £1.08m. The couple are left with 50,464 shares in British Land.
Read moreShaftesbury boss invests £100,000
4th Mar 2011 17:03
Shaftesbury chief executive Jonathan Lane has invested a further £100,000 in the property investor. Lane has bought 22,222 shares at 450p each. That takes his stake to 966,233 shares, which is worth £4.3m at the latest purchase price. Lane raised just over £99,000 from the sale of option shares la
Read moreUK SMALLCAP ROUNDUP: E-Therapeutics Seeks Pharma Alliances
29th Jun 2010 16:00
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps E-THERAPEUTICS PLC (ETX.LN), a U.K. drug developer, said Tuesday its focus this year and next will be on clinical trials of its experimental medicines an
Read more